Market Research Blog

According to the forecast presented in the report, valuation of the global measurement technology in downstream processing market is anticipated to increase from an estimated US$ 3,772.4 Mn in 2022 to about US$ 6,827.9 Mn by the end of the forecast period in 2028. This reflects a CAGR of 6.1% in terms of value during the period of study.

To remain ‘ahead’ of your competitors, request for a sample

Sensors Dominant Product Type in the Global Measurement Technology in Downstream Processing Market

The global measurement technology in downstream processing market is segmented on the basis of product type into Sensors, Transmitters and Controllers, Sensor Housings, Cables and Connectors, and Buffers and Standard Reagents. Sensors are the widely adopted product type with an increased market share throughout the forecast period. Conductivity sensors and cell density sensors are two of the fastest growing sensor types. In 2022, the market volume of the sensors segment was pegged at 4,165.4 (‘000 units) and this is expected to increase to 8,094.9 (‘000 units) by 2028 end.

Single Use to Remain the Most Preferred Modality in the Global Measurement Technology in Downstream Processing Market

On the basis of modality, the global market is segmented into Single Use and Reusable. The single use segment is the fastest growing modality type with a CAGR of 6.9%.

Biopharmaceutical Companies the Fastest Growing End Users of Measurement Technology in Downstream Processing

The global market for measurement technology in downstream processing is segmented based on end user into Biopharmaceutical Companies, Food & Beverage Companies, Contract Manufacturing Organisations, Contract Research Organisations, Academic and Research Institutes, and Others. Biopharmaceutical companies are the largest end users of measurement technology in downstream processing, and this segment is slated to register a CAGR of 7.2% during the forecast period – the highest among all the end user segments of the global market. Food & beverage companies are the second largest end users of measurement technology in downstream processing, and this segment is expected to reach a market valuation of US$ 2,273.2 Mn by 2027 end.

Western Europe Largest Regional Market for Measurement Technology in Downstream Processing

The report studies the performance of the global measurement technology in downstream processing market across the key geographies of North America, Latin America, Western Europe, Eastern Europe, Asia Pacific Excluding Japan, Japan, and Middle East & Africa. The Western Europe regional market is the largest in terms of revenue, with an estimated market valuation to the tune of US$ 2,677.1 Mn by the end of 2027. However, the Asia Pacific Excluding Japan measurement technology in downstream processing market is projected to witness the fastest growth rate of 8.3% between 2017 and 2027.

Major Key Players:

• Applikon Biotechnology Inc.
•  Sartorius AG
• Broadley-James Corporation
•  Thermo Fisher Scientific Inc.
• Hamilton Company
• Waters Corporation
• PreSens Precision Sensing GmbH
• PendoTECH LLC
• Endress+Hauser AG
• Mettler-Toledo International Inc.
• Metroglas AG
• Madison
• YSI
• Evoqua
• Sensorex
• Forbes

Get a Customized Scope to Match Your Need Ask an Expert @ https://www.futuremarketinsights.com/ask-question/rep-gb-5922

Measurement technology in downstream processing market by Category

By Product

• Sensors
  • pH Sensors
    • Optical
    • Electrochemical
  • DO Sensors
    • Optical
    • Eelctrochemical
  • Conductivity Sensors
  • Cell Density Sensors

• Sensor Housings
• Transmitters & Controllers
• Cables & Connectors
• Buffers & Reagents

By Modality

• Single-use
• Reusable

By End User      

• Pharmaceutical & Biotechnology Companies
• Food & Beverage Companies
• Contract Manufacturing Organizations
• Academic & Research Institutes
• Others

For critical insights, request for PDF Brochure @ https://www.futuremarketinsights.com/reports/brochure/rep-gb-5922

By Region

• North America
• Latin America
• Western Europe
• Eastern Europe
• Asia-Pacific excluding Japan
• Japan
• Middle East & Africa

Acute varicella may be complicated by secondary bacterial skin infections, cerebellitis, encephalitis, haemorrhagic complications, and viral and bacterial pneumonia. The climate is a core factor that seems to have an impact on the epidemiology of varicella. In most of the temperate climatic regions, 90% of the people are infected before adolescence. In tropical climates, VZV infection occurs later in life and adults are more susceptible to it than children.

On the other hand, herpes zoster or shingles is a sporadic disease that is caused by the reactivation of latent VZV in the sensory nerve ganglia. It is usually self-limiting and is categorised by severe pain with dermatomal distribution and at times followed by post-herpetic neuralgia that can be chronic and debilitating among the geriatric population. Though herpes zoster can occur at any age, most of the cases are reported after the age of 50 along with increasing risks of complications.

In order to cater to the needs of the patients and provide a potential treatment for this infection, companies are entering into strategic partnerships in order to make use of the technology of the other leading companies and are also focussing on research and development.

To remain ‘ahead’ of your competitors, request for a sample 

For instance, in December 2016, Slayback and Sandoz signed an agreement with Novartis AG for the sale and marketing rights of Slayback Generic Zovirax Ointment (Acyclovir Ointment). Per the agreement Novartis obtained the sales and marketing rights, which increased their position in the market. Other leading companies operating in the market are

• Valeant Pharmaceuticals International Inc.
• Teva Pharmaceutical Industries Ltd
• Pfizer Inc.
• Mylan N.V.
• Abbott Laboratories
• GlaxoSmithKline Plc.
• Dr. Reddy’s Laboratories Ltd.

According to the report, the global varicella zoster infection treatment market is expected to register a 4.2% CAGR from 2017 to 2027. In 2016, the market was worth US$ 1,257.1 Mn and is expected to reach a valuation of US$ 1,969.1 Mn by the end of 2027.

Risk of Varicella in Pregnancy and the Need to Adhere to the Guidelines of Chickenpox Treatment to Bode Well for the Market

Primary infection with varicella zoster in pregnancy may cause maternal mortality or serious morbidity issues. A particular guideline issued in 2015 assesses the evidence regarding maternal and foetal risks of varicella zoster virus infection in pregnancy. The U.K. Advisory Group and Swiss and Canadian national guidelines prescribe procedures for the use of antiviral drugs in pregnancy. The U.K. Advisory Group provides guidelines for chickenpox as well.

These guidelines recommend oral acyclovir, which should be prescribed for pregnant women within 24 hours once they present the onset of the rash and if they have 20+0 weeks of gestation or beyond. Guidelines are unanimous nevertheless, in recommending that intravenous acyclovir be administered in cases of severe maternal infection. This factor along with the fact that the rate of exposure and transmission is extremely high in this infection and is a threat for pregnant women and kids, is expected to boost the growth of the varicella zoster infection treatment market.

Natural Products to Challenge Market Growth

Several people opt for other treatment options for herpes zoster and varicella. These alternative treatment options are expected to hamper the growth of the antiviral drugs market for varicella zoster infection treatment. Homeopathy, supplements, and other natural herbal medicines are used to treat herpes zoster and varicella.